Government panel recommends mixing Bharat Biotech's Covaxin and nasal vaccine in trials

The subject expert committee (SEC) under India's drug regulator gave its go-ahead to Hyderabad-based Bharat Biotech to conduct the phase 2/3 clinical trials, administering a dose each of Covaxin and the adenoviral intranasal vaccine with an interval between the two.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2TKsSCh
via IFTTT